Recombinant follicular stimulating hormone plus recombinant luteinizing hormone versus human menopausal gonadotropins- does the source of LH bioactivity affect ovarian stimulation outcome?

• Published in: Reproductive biology and endocrinology Vol. 19; no. 1; p. 182
• Main Authors: Kirshenbaum, M, Gil, O, Haas, J, Nahum, R, Zilberberg, E, Lebovitz, O, Orvieto, R
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 09.12.2021; BioMed Central; BMC
• Subjects: Adult; Assisted reproductive technology; Biological activity; Chorionic gonadotropin; Cross-Sectional Studies; Embryos; Female; Fertility drugs; Fertilization in Vitro - methods; Follicle Stimulating Hormone - administration & dosage; Follicle-stimulating hormone; Glycoproteins; Gonadotropins; Hormones; Human chorionic gonadotropin; Humans; Intracellular signalling; Luteinizing hormone; Luteinizing Hormone - administration & dosage; Medical research; Medicine, Experimental; Menopause; Menotropins - administration & dosage; Oocytes; Ovarian stimulation; Ovaries; Ovulation; Ovulation Induction - methods; Patients; Pituitary (anterior); Pregnancy; Pregnancy Rate; Recombinant Proteins - administration & dosage; Reproductive technologies; Standard deviation; Steroids; Treatment Outcome; Luteinizing hormone; Gonadotropins; Assisted reproductive technology; Ovarian stimulation; Human chorionic gonadotropin
• ISSN: 1477-7827; 1477-7827
• DOI: 10.1186/s12958-021-00853-7

Luteinizing hormone (LH) and human chorionic gonadotropin (hCG) activate distinct intracellular signaling cascades. However, due to their similar structure and common receptor, they are used interchangeably during ovarian stimulation (OS). This study aims to assess if the source of LH used during OS affects IVF outcome. This was a cross sectional study of patients who underwent two consecutive IVF cycles, one included recombinant follicular stimulating hormone (FSH) plus recombinant LH [rFSH+rLH, (Pergoveris)] and the other included urinary hCG [highly purified hMG (HP-hMG), (Menopur)]. The OS protocol, except of the LH preparation, was identical in the two IVF cycles. The rate of mature oocytes was not different between the treatment cycles (0.9 in the rFSH+rLH vs 0.8 in the HP-hMG, p = 0.07). Nonetheless, the mean number of mature oocytes retrieved in the rFSH+rLH treatment cycles was higher compared to the HP-hMG treatment cycles (10 ± 5.8 vs 8.3 ± 4.6, respectively, P = 0.01). Likewise, the mean number of fertilized oocytes was higher in the rFSH+rLH cycles compared with the HP-hMG cycles (8.5 ± 5.9 vs 6.4 ± 3.6, respectively, p = 0.05). There was no difference between the treatment cycles regarding the number of top-quality embryos, the ratio of top-quality embryos per number of oocytes retrieved or fertilized oocytes or the pregnancy rate. The differences in treatment outcome, derived by different LH preparations reflect the distinct physiological role of these molecules. Our findings may assist in tailoring a specific gonadotropin regimen when assembling an OS protocol.